Cochrane Renal Group

 Back
autoid 20
crg_id CRG080500009
titleoftrial The comparative effects of Atenolol and Nebivolol on renal function in patients with Diabetic Nephropathy
acronymnoftrial
website http://
identificationno
leadprefix Dr
leadsurname Riley
leadgivennames Stephen G
leadposition Senior Lecturer in Nephrology
leaddepartment Institute of Nephrology
leadorganisation University Hospital of Wales
leadaddress Heath Park, Cardiff, CF14 4XN Wales
leademail rileysg@cf.ac.uk
leadphone +44 2920748467
leadfax +44 2020748470
leadsuffix
contactprefix
contactsurname
contactgivennames
contactposition
contactdepartment
contactorganisation
contactaddress
contactemail
contactphone
contactfax
funding industry
otherfunding
fundingnameofsponsors Menarini Inc
ethicsapproval yes
studytype randomised
studytype_other
groupassignment crossover
blinding_patients no
blinding_investigators yes
blinding_outcomes yes
blinding_analysts yes
proposedstart 09/2005
actualstart
proposedcompletiondate 06/2006
actualcompletiondate
multi_center_study no
numberofcentres
multi_national_study no
countrycentres Wales
researchquestion Does the vasodilating beta blocker Nebivolol have positive effects on renal function when compared to Atenolol.
study_status_recruitment not_yet_recruiting
study_status_recruitment_follow
healthcarecondition Diabetic nephropathy
intervention1 Nebivolol
intervention2 Atenolol
intervention3
intervention4
participants_gender both
participants_other adults
age 18-80
totalrecruitment 15
inclusion Diabetes
Proteinuria from 0.5-5g/24hr
Est Creatinine clearance 35-70ml/min
exclusion Poorly controlled hypertension
Other known renal disease
Pregnancy
primaryoutcomes Isotope GFR and ERPF on Atenolol and Nebivolol
secondaryoutcomes Changes in Arterial function on Atenolol and Nebivolol
reference